Roivant Sciences (NASDAQ:ROIV) Reaches New 1-Year High – Still a Buy?

Roivant Sciences Ltd. (NASDAQ:ROIV) reached a new 52-week high on Tuesday . The stock traded as high as $28.08 and last traded at $27.9030, with a volume of 683207 shares traded. The stock had previously closed at $27.76.

Analyst Upgrades and Downgrades

ROIV has been the topic of several research reports. Jefferies Financial Group restated a “buy” rating and set a $30.00 price target on shares of Roivant Sciences in a research report on Monday, February 9th. Guggenheim boosted their target price on shares of Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a report on Monday, February 9th. TD Cowen reissued a “buy” rating on shares of Roivant Sciences in a research report on Saturday, February 7th. HC Wainwright boosted their price objective on shares of Roivant Sciences from $26.00 to $33.00 and gave the stock a “buy” rating in a research note on Tuesday, February 10th. Finally, The Goldman Sachs Group raised their target price on shares of Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $28.69.

Roivant Sciences Stock Down 1.6%

The stock has a market capitalization of $20.18 billion, a PE ratio of -24.10 and a beta of 1.22. The firm’s fifty day moving average price is $23.66 and its two-hundred day moving average price is $19.26.

Insider Buying and Selling

In other Roivant Sciences news, Director Daniel Allen Gold sold 375,784 shares of the firm’s stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $26.50, for a total transaction of $9,958,276.00. Following the sale, the director owned 15,127,329 shares in the company, valued at approximately $400,874,218.50. This trade represents a 2.42% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $26.49, for a total value of $5,298,000.00. Following the completion of the transaction, the chief executive officer owned 1,654,597 shares in the company, valued at $43,830,274.53. The trade was a 10.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 13,318,014 shares of company stock worth $315,727,023. Corporate insiders own 10.80% of the company’s stock.

Institutional Trading of Roivant Sciences

Several hedge funds have recently bought and sold shares of ROIV. Jones Financial Companies Lllp grew its holdings in Roivant Sciences by 226.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after buying an additional 1,148 shares in the last quarter. SBI Securities Co. Ltd. increased its position in Roivant Sciences by 1,740.3% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after purchasing an additional 1,166 shares during the last quarter. Allworth Financial LP raised its stake in Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after purchasing an additional 583 shares in the last quarter. Bessemer Group Inc. raised its stake in Roivant Sciences by 41.5% during the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares in the last quarter. Finally, CWM LLC lifted its position in Roivant Sciences by 44.6% during the second quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after purchasing an additional 920 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.